| Quantity | 1Set | 100mg, 5mg, 2mg, 1mg, 25mg | 1ml | 10mg, 5mg, 50mg, 1mg, 25mg | 100µg, 10µg, 500µg, 50µg, 1mg |
| Description | FBLL1 Human Pre-designed siRNA Set A contains three designed siRNAs for FBLL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components FBLL1 siRNA-1: 5 nmol (HPLC) FBLL1 siRNA-2: 5 nmol (HPLC) FBLL1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:FBLL1 Human Pre-designed siRNA Set A contains three designed siRNAs for FBLL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components FBLL1 siRNA-1: 5 nmol (HPLC) FBLL1 siRNA-2: 5 nmol (HPLC) FBLL1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | Extinction Coeff.A280 nm = 1.0 at 1.0 mg/mLSpecificityMonospecific for Factor B in human plasma and serumGeneral DescriptionProduct is whole polyclonal antiserum from goats immunized with highly purified human complement protein. Product is not a purified IgG fraction. Goats are maintained in FDA Extinction Coeff.A280 nm = 1.0 at 1.0 mg/mLSpecificityMonospecific for Factor B in human plasma and serumGeneral DescriptionProduct is whole polyclonal antiserum from goats immunized with highly purified human complement protein. Product is not a purified IgG fraction. Goats are maintained in FDA certified facilities.Physical Characteristics & StructureAntibodies present in the antisera are primarily IgGApplicationsWestern Blots: Effective at dilutions 1/4,000 to 1/8,000 depending on conditions.Most effective against non-reduced antigen.ELISA: Effective at dilutions 1/8,000 to 1/16,000 depending on conditions.Immunodiffusion: Effective against NHS and plasma at 1/16 dilution... Read More | Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis... Read More | Purity>97% by SDS-PAGE and HPLC analyses.FunctionPlays an important role in the organization of the cytoskeleton (By similarity). Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization. Seraspenide inhibits the entry of hematopoeitic pluripotent stem cells Purity>97% by SDS-PAGE and HPLC analyses.FunctionPlays an important role in the organization of the cytoskeleton (By similarity). Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization. Seraspenide inhibits the entry of hematopoeitic pluripotent stem cells into the S-phase... Read More |